公开(公告)号：US12215147B2

公开(公告)日：2025-02-04

申请号：US17409639

申请日：2021-08-23

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Laurens Kruidenier ,  Mahyar Sabripour ,  Janine Bilsborough ,  Dermot P. McGovern ,  Dalin Li

IPC: C12Q1/6883 ,  A61P1/00 ,  A61P1/04 ,  C07K16/24 ,  C07K16/28 ,  A61K39/00

Abstract: Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

公开(公告)号：US11999789B2

公开(公告)日：2024-06-04

申请号：US17682922

申请日：2022-02-28

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jeffry D. Watkins ,  Cindy T. Dickerson ,  Rafael Rojas ,  Matthew Reissman ,  Patricia McNeeley ,  Janine Bilsborough ,  Bradley Henkle ,  Stephan R. Targan

IPC: C07K16/24 ,  A61P1/04 ,  C07K16/28 ,  A61K39/395 ,  C07K14/52 ,  C07K14/525

CPC classification number: C07K16/2875 ,  A61P1/04 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

公开(公告)号：US20230192835A1

公开(公告)日：2023-06-22

申请号：US17931049

申请日：2022-09-09

Applicant: Prometheus Biosciences, Inc. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jeffry D. Watkins ,  Cindy T. Dickerson ,  J. Monty Watkins ,  Patricia McNeeley ,  Janine Bilsborough ,  Bradley Henkle ,  Stephan R. Targan

IPC: C07K16/24 ,  A61P1/04 ,  C07K16/28 ,  A61P1/00 ,  A61K9/00 ,  C12N15/09 ,  C12N15/63 ,  C12N5/10

CPC classification number: C07K16/24 ,  A61P1/04 ,  C07K16/241 ,  C07K16/28 ,  A61P1/00 ,  A61K9/0019 ,  C07K16/2875 ,  C12N15/09 ,  C12N15/63 ,  C12N5/10 ,  A61K39/3955

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

公开(公告)号：US20230018729A1

公开(公告)日：2023-01-19

申请号：US17409639

申请日：2021-08-23

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Laurens KRUIDENIER ,  Mahyar SABRIPOUR ,  Janine BILSBOROUGH ,  Dermot P. MCGOVERN ,  Dalin LI

IPC: C07K16/24 ,  A61P1/04 ,  C12Q1/6883 ,  A61P1/00 ,  C07K16/28

Abstract: Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

公开(公告)号：US11136386B2

公开(公告)日：2021-10-05

申请号：US17118441

申请日：2020-12-10

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Laurens Kruidenier ,  Mahyar Sabripour ,  Janine Bilsborough ,  Dermot P. McGovern ,  Dalin Li

IPC: C12Q1/6883 ,  A61P1/00 ,  C07K16/28 ,  C07K16/24 ,  A61P1/04 ,  A61K39/00

Abstract: Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

公开(公告)号：US20200264171A1

公开(公告)日：2020-08-20

申请号：US16614752

申请日：2018-05-31

Applicant: PROMETHEUS BIOSCIENCES, INC.

Inventor： Anjali JAIN ,  Venkateswarlu KONDRAGUNTA ,  Michael Hale

IPC: G01N33/564 ,  G01N33/68

Abstract: of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

公开(公告)号：US20200241006A1

公开(公告)日：2020-07-30

申请号：US16755090

申请日：2018-10-09

Applicant: PROMETHEUS BIOSCIENCES, INC.

Inventor： Snehal U. NAIK ,  Anjali JAIN

IPC: G01N33/68

Abstract: The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

公开(公告)号：US10697961B2

公开(公告)日：2020-06-30

申请号：US15161024

申请日：2016-05-20

Applicant: Prometheus Biosciences, Inc. ,  KATHOLIEKE UNIVERSITEIT LEUVEN

Inventor： Steven Lockton ,  Marc Ferrante ,  Severine Vermiere ,  Sharat Singh

IPC: G01N31/00 ,  G01N33/53 ,  G01N33/564

Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.

公开(公告)号：US10571467B2

公开(公告)日：2020-02-25

申请号：US15486072

申请日：2017-04-12

Applicant: Prometheus Biosciences, Inc.

Inventor： Sharat Singh ,  Venkateswarlu Kondragunta

IPC: G01N33/564 ,  G01N33/50 ,  G01N33/68 ,  G01N33/94

Abstract: In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

公开(公告)号：US11866505B2

公开(公告)日：2024-01-09

申请号：US17822598

申请日：2022-08-26

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  DR. FALK PHARMA GMBH

Inventor： Jessie-Farah Fecteau ,  Mark Renshaw ,  Johan Fransson ,  Olivier Laurent ,  Burton Barnett

IPC: C07K16/24 ,  C07K16/28 ,  A61P37/06 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61P37/06 ,  C07K16/2875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).